| Statin Use in Myelodysplastic Syndromes Is Associated with a Better Survival and Decreased Progression to Leukemia |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists |
|
Annals of Hematology |
Myelodysplastic Syndromes (MDS) |
| Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study |
|
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes |
|
Hematology/oncology and stem cell therapy |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| T cell dysfunctions in myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| T-cell dysfunctions in myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions |
|
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
| Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions |
|
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
